“Finally,
knowledge of the source of takeover gains still eludes us.” (Jensen &
Ruback, 1983)
It is a known fact that global economic development is a
driving force for international mergers and acquisitions (M&A) activity.
For the 4th quarter of 2019, Bloomberg estimated a 19% GDP and a
12.5% policy interest rate depreciation compared to the 3rd quarter.
Taking this data, the further ongoing global political uncertainty due to
Brexit and several market events like the cancelled multi-billion tobacco
merger between Altria and Philip Morris into consideration, it does not seem
surprising that the global M&A activity has fallen 11 per cent by the 3rd
quarter 2019 in comparison to the previous year, presenting a 2 year low in
terms of deal value (FT). Although those numbers may not directly imply
prosperous business activities, 2019 was still characterized by several US publicly
listed mega-mergers: The $89.5bn purchase of the pharma company Celgene by its
direct competitor Bristol-Myers Squibb, the $88.9bn armaments concern merger
between United Technologies and Raytheon and lastly, the $86.3bn fusion between
the pharma giants AbbVie and Allergan. It seems obvious that one could believe
the former mentioned economic and business developments have put pressure on
the performance of the executed multi-billion-dollar mergers. In the following,
I want to explore the actual short-term historic performance of 2019’s two biggest
deals, taking into consideration major deal characteristics and furthermore, discussing
possible alternative managerial firm-specific value drivers.
Figure 1. Global dealmaking numbers. Reprinted from Financial Times, by E. Platt, J. Fontanella-Khan, L. Noonan & A. Massoudi, 2019, https://www.ft.com |
First of all, it is important to examine the research on historic
M&A performance. The 1983 conducted meta-study by Jensen & Ruback delivered
statistically significant evidence on shareholder gains or losses after takeovers,
concluding that acquiring company shareholders make regular short and long-term
losses while target company shareholders make significant gains in value. Moreover,
empirical studies suggest that when it comes to M&A financing methods, share-based
takeovers underperform compared to cash-based acquisitions (Fischer, 2017). Reasons
for this may be due to deal value preciseness or acquiring shareholders’ retainment
of company control. When looking at 2019’s two biggest deals now, the numbers paint
a surprisingly different picture:
The 5 months after each merger-announcement daily price data
(Bloomberg) of each acquiring company suggest periodical positive geometric
returns of 3.61% and 16.30%, respectively for Bristol-Myers Squibb and United
Technologies. Taking into consideration the companies’ required capital return of
the same 5 monthly period, calculated by the use of CAPM (See blog post from 03.11.19)
with an overridden periodical beta, the 2 companies generate excess returns of
0.59% and 13.7%. Therefore, especially the United Technologies and Raytheon
fusion created substantial short-term shareholder value, although the global economic
state and conducted research might have implied different results. Additionally,
the strong performance of both acquirers can not be explained in the context of
M&A financing research as Bristol-Myers Squibb purchased with a
well-balanced 53% to 47% Stock-Cash mix while United Technologies even financed
its merger with a 100% stock payment.
Without doubt, my short analyses of those 2 recent mega-events
in the M&A industry are due to its way too small number of observations not
statistically representable at all. Although, they do symbolically represent a
recent development in M&A research. While the study of specific deal
characteristics like the aforementioned financing methods or political and
regulatory effects have been researched for decades, more and more academics use
a different approach, considering mainly firm-specific managerial
characteristics for explaining shareholder wealth creation in M&A. “Extraordinary
acquirers”, a paper published by Golubov, Yawson & Zhang in 2015, is one interesting
example of this new school of thought. The three academics conclude that firm-specific
fixed effects match, partially even overshadow, the explanatory power of
important deal-characteristics. Going more into detail, they deduce that positive
and negative acquirer returns are firm-specifically persistent over time and that
they are also persistent under new managerial influences due to changes of the
CEO. Golubov et al. explain those findings mainly by firm-specific organizational
knowledge in form of M&A development teams and expertise in post-merger
integration, by “bidder-specific synergies, […], derived from the nature of the
firm’s assets or its business model that are particularly well-suited for
acquisitions” and lastly, by prior success in acquisitions that may facilitate
future M&A activities.
Bibliography
Fischer, M. (2017). The source of financing in mergers
and acquisitions. The Quarterly Review of Economics and Finance, 65, 227-239.
Golubov , A., Yawson,
A., & Zhang, H. (2015). Extraordinary acquirers. Journal of Financial
Economics, 116(2), 314-330.
Jensen, M. C., &
Ruback, R. S. (1983). The market for corporate control: The scientific
evidence. Journal of Financial economics, 11(1-4), 5-50.